At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Indacaterol maleate +2 moredrug
Likely dose
Indacaterol maleate 150 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Three-period Cross-over Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts (Maleate and Acetate) Delivered Via the Concept1 Inhalation Device in Patients With Asthma
In Brief
A Phase 2 clinical trial evaluating Indacaterol maleate, Indacaterol acetate, and 1 other intervention for Asthma. Completed, enrolled 54 participants across 6 sites.
Detailed Summary
This study is a randomized, double-blind, placebo-controlled, three-period cross-over study in approximately 54 subjects with asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionJan 2018
Study CompletionJan 2018
TodayJul 2026
First PostedAug 22, 2017
Enrollment StartSep 5, 2017
Primary CompletionJan 17, 2018
Study CompletionJan 18, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.9 years ago
Interventions
Indacaterol maleatedrug
150 μg via Concept1 device
Indacaterol acetatedrug
150 μg via Concept1 device
Placebodrug
Capsule containing no active ingredients delivered via Concept1 device